phesgo 1200mg/600mg/30.000 units s.c. sol. for inj. 15 ml
فيزجو 1200مجم/600مجم/30.000 وحدة 15 مل
pertuzumab+trastuzumab+hyaluronidaseThe published official price. Pharmacies may differ slightly.
- Strength
- 1200mg + 600mg
- Form
- syringe
- Manufacturer
- roche
- Route
- injection
The medical information below is guidance and may be incomplete or wrong. Do not change your medicine or dose based on it — ask a pharmacist or doctor.
Uses
Used with chemotherapy for HER2-positive early breast cancer and with docetaxel for HER2-positive metastatic breast cancer. It is indicated in selected patients as part of HER2-targeted therapy.
Do not use if
Hypersensitivity to pertuzumab, trastuzumab, hyaluronidase, or any component of the formulation.
Side effects
Common adverse effects include diarrhea, fatigue, nausea, alopecia, injection-site reactions, and neutropenia. Serious cardiac, pulmonary, and hypersensitivity reactions may occur.
Warnings
May cause cardiomyopathy, embryo-fetal toxicity, and pulmonary toxicity. Cardiac monitoring is required during treatment.
How it works
Pertuzumab and trastuzumab target different HER2 receptor domains and inhibit tumor cell signaling. Hyaluronidase facilitates subcutaneous administration.
Storage
Store refrigerated at 2°C to 8°C in the original carton. Do not freeze or shake.